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The Tigecycline Evaluation and Surveillance Trial is a global surveillance study monitor-
ing  the efﬁcacy of tigecycline and comparators against clinically important pathogens.
Between 2004 and 2010, 3126 isolates of Staphylococcus aureus were collected from 66 cen-
ters in 13 countries in Latin America; of these, 1467 (46.9%) were resistant to methicillin.
The main contributors of S. aureus isolates were Mexico (n = 846), Argentina (n = 740), and
Colombia (n = 445). The methicillin-resistant S. aureus rate was greater than 50% in ﬁve
countries, the highest reported in Puerto Rico (73.9%). Methicillin-resistant S. aureus rates
across Latin America ranged from 40.1% to 50.6% over the study period. All S. aureus iso-
lates  were susceptible to linezolid and vancomycin, while 100% of methicillin-susceptible S.
aureus isolates and 99.8% of methicillin-resistant S. aureus isolates were susceptible to tige-
cycline. Both methicillin-susceptible S. aureus and methicillin-resistant S. aureus were highly
susceptible to minocycline (99.2% and 97.0%, respectively). Latin American methicillin-
susceptible S. aureus were highly susceptible to levoﬂoxacin (94.6%) while only 16.2% ofmethicillin-resistant S. aureus were levoﬂoxacin-susceptible. This study shows that line-
zolid, vancomycin, and tigecycline are all highly active against S. aureus from Latin America,
regardless of methicillin resistance.
© 2013 Elsevier Editora Ltda. All rights reserved.
such as RESISTNET, SENTRY, T.E.S.T. [Tigecycline Evaluationntroduction
taphylococcus aureus is a common component of the human
acterial ﬂora, and can exist both as a harmless colonizer and
s an active infective pathogen. S. aureus may cause a number
f infections, including skin and soft tissue infections, bone,
oint and implant infections, pneumonia, septicemia, and
1oxic shock syndrome. S. aureus is an important pathogen
ue in part to the spread of antimicrobial resistant strains,
ormally deﬁned as methicillin-resistant S. aureus (MRSA);
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ttp://dx.doi.org/10.1016/j.bjid.2012.08.017these strains are often multidrug-resistant (MDR) and are
associated with increased morbidity, mortality, and treatment
costs.2–4
MRSA is the leading cause of nosocomial infections in
Latin America, and community-based infections associated
with MRSA are increasing in frequency.5 Several Latin Amer-
ican centers participate in long-term surveillance studiesand Surveillance Trial], and ZAAPS [Zyvox Annual Appraisal
of Potency and Spectrum]. However, the real extent and
importance of MRSA infections in the region are not fully
served.
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understood as a large proportion of the region’s population
receives medical care from small healthcare centers which
do not have the resources to contribute data to surveillance
studies.6
Surveillance studies such as T.E.S.T. are essential in moni-
toring changes in the distribution and prevalence of important
pathogens such as MRSA. In an attempt to better understand
susceptibility patterns among S. aureus collected across Latin
America, we  examine and describe here changes in in vitro sus-
ceptibility among isolates of S. aureus and MRSA collected in
Latin America as part of T.E.S.T. between 2004 and 2010. Data
are described for the region as well as for individual countries,
both longitudinally and over the complete course of the study
period. This report builds upon the summary of antimicrobial
resistance among Gram-positive and Gram-negative isolates
collected in Latin America between 2004 and 2007 published
by Rossi et al.7
Methods
Bacterial  isolates
Bacterial isolates were collected in 13 Latin American
countries as a part of T.E.S.T. between 2004 and 2010 (2010 data
are incomplete, as some centers had not yet provided isolates
at the time of writing). In this manuscript, we examine iso-
lates of S. aureus collected in Argentina (12 centers), Brazil (3
centers), Chile (5 centers), Colombia (14 centers), El Salvador (1
center), Guatemala (4 centers), Honduras (2 centers), Jamaica
(1 center), Mexico (14 centers), Nicaragua (1 center), Panama
(2 centers), Puerto Rico (1 center), and Venezuela (6 centers).
The degree of participation among the 66 centers contribut-
ing isolates to this study was as follows: 1 center contributed
in all 6 years (Mexico); 6 centers contributed in 5 years (Mex-
ico and Argentina, 2 each; Brazil and Chile, 1 each); 6 centers
contributed in 4 years (Argentina, 4; Guatemala and Chile, 1
each); 8 centers contributed in 3 years (Argentina, Mexico, and
Venezuela, 2 each; Brazil and Panama, 1 each); 25 centers con-
tributed in 2 years; and 20 centers contributed in a single year
only.
Each participating center was required to collect 25 isolates
of S. aureus determined by local criteria to be of clinical signif-
icance. Only a single isolate per patient was admitted into the
study. Isolate inclusion was independent of age, sex, and/or
previous medical history. Acceptable isolate sources included
urine (limited to no more  than 25% of all isolates), blood, respi-
ratory tract, skin, wound, and ﬂuids from originally sterile
body sites.
Antimicrobial  susceptibility
Minimum inhibitory concentrations (MICs) for all isolates
were determined locally using broth microdilution method-
ology (Sensititre® plates [TREK Diagnostic Systems, West
®Sussex, England] or MicroScan panels [Siemens, Sacramento,
CA, USA]) as described in the guidelines published by the Clin-
ical and Laboratory Standards Institute (CLSI).8 Antimicrobial
susceptibility was determined according to CLSI interpretive 0 1 3;1 7(1):13–19
criteria.9 S. aureus ATCC 29213 was used for quality control
studies.
The T.E.S.T. antimicrobial panel for S. aureus included
the following antimicrobial agents: amoxicillin-clavulanate,
ampicillin, ceftriaxone, imipenem (MicroScan® only), levoﬂox-
acin, linezolid, meropenem (Sensititre® only), minocycline,
penicillin, piperacillin-tazobactam, tigecycline, and van-
comycin. Data for beta-lactam antimicrobials are not included
in this manuscript due to their inactivity against MRSA.
Isolate collection and transport were coordinated by Lab-
oratories International for Microbiology Studies, a division
of International Health Management Associates, Inc. [IHMA,
Schaumburg, IL, USA]). IHMA were also responsible for identity
conﬁrmation as well as the development and management of
a centralized database for all isolates.
Results
A total of 3126 isolates of S. aureus were collected across Latin
America between 2004 and 2010; 1467 (46.9%) were identiﬁed
as methicillin-resistant (Table 1). The greatest numbers of S.
aureus isolates were contributed by Mexico (n = 846), Argentina
(n = 740), and Colombia (n = 445). MRSA prevalence reached 50%
or more  in ﬁve countries, with the highest rate reported in
Puerto Rico (73.9%).
S. aureus numbers were lower in 2010 than in most pre-
ceding years as 2010 data were incomplete at the time of
writing. Yearly MRSA rates ranged from 40.1% to 50.6% across
Latin America during the study interval with no noticeable
geographical trends seen (data not shown). Large variations
in MRSA prevalence were noticed in several countries from
year to year, most notably Mexico (24.1–80.0%) and Venezuela
(19.0–69.8%).
All S. aureus isolates in this study were susceptible to
linezolid and vancomycin. Susceptibility to tigecycline across
Latin America was also very high: 100% of MSSA isolates were
tigecycline susceptible while only 3 isolates of MRSA were
non-susceptible. Of the three tigecycline non-susceptible
isolates, two (collected in El Salvador in 2009) had a tigecy-
cline MIC  of 2 mg/L while the third (collected in Honduras in
2009) had a tigecycline MIC  of 1 mg/L. All three isolates were
also non-susceptible to levoﬂoxacin. Data for linezolid, van-
comycin, and tigecycline are not presented in table form here.
Longitudinal in vitro activity for levoﬂoxacin and minocy-
cline against MSSA and MRSA from Latin America between
2004 and 2010 are listed in Table 2. Although 94.6% of
MSSA isolates were susceptible to levoﬂoxacin, only 16.2%
of MRSA isolates were levoﬂoxacin-susceptible during this
period. MSSA susceptibility to levoﬂoxacin was high but
decreased from 100% in 2004 to 91.2% in 2010. MRSA sus-
ceptibility to levoﬂoxacin was notably lower, rarely exceeding
40% in any country in a single year; over the collection period,
MRSA susceptibility was extremely low (≤6.4%) in Brazil, Chile,
El Salvador, Guatemala Honduras, and Mexico. While levo-
ﬂoxacin susceptibility in Argentina decreased among MSSA
isolates (from 100% in 2004 to 82.4% in 2010), it increased
among MRSA isolates (from 3.6% in 2004 to 34.4% in 2009).
MRSA susceptibility across Latin America increased from 3.4%
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Table 1 – Numbers of isolates of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) across Latin America
between 2004 and 2010.
Country Year S. aureus (n) MRSA
n %
Argentina 2004  64 28 43.8
2005 158 72 45.6
2006 56 26 46.4
2007 149 74 49.7
2008 174 86 49.4
2009 118 64 54.2
2010 21 4 19.0
Combined 740 354 47.8
Brazil 2005 49 30 61.2
2006 25 15 60.0
2007 25 10 40.0
2008 61 35 57.4
2009 80 36 45.0
2010 1 1 –
Combined 241 127 52.7
Chile 2005 38 15 39.5
2006 40 25 62.5
2007 72 57 79.2
2008 45 21 46.7
2009 48 32 66.7
Combined 243 150 61.7
Colombia 2005 6 2 –
2006 72 40 55.6
2007 21 7 33.3
2008 163 61 37.4
2009 124 45 36.3
2010 59 10 16.9
Combined 445 165 37.1
El Salvador 2009  34 19 55.9
Combined 34 19 55.9
Guatemala 2004 1 1 –
2006 37 23 62.2
2007 28 21 75.0
2008 27 22 81.5
2009 88 53 60.2
Combined 181 120 66.3
Honduras 2006 9 4 –
2007 13 2 15.4
2009 39 23 59.0
Combined 61 29 47.5
Jamaica 2006 25 4 16.0
Combined 25 4 16.0
Mexico 2005 15 12 80.0
2006 168 73 43.5
2007 112 27 24.1
2008 272 107 39.3
2009 212 94 44.3
2010 67 44 65.7
Combined 846 357 42.2
Panama 2006 25 11 44.0
2007 24 6 25.0
2008 26 10 38.5
2009 21 4 19.0
Combined 96 31 32.3
Puerto Rico 2006  23 17 73.9
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Table 1 (Continued )
Country Year S. aureus (n) MRSA
n %
Combined 23 17 73.9
Venezuela 2006 21 4 19.0
2007 47 11 23.4
2008 29 15 51.7
2009 86 60 69.8
2010 4 2 –
Combined 187 92 49.2
Latin Americaa 2004 65 29 44.6
2005 266 131 49.2
2006 505 244 48.3
2007 491 215 43.8
2008 797 357 44.8
2009 850 430 50.6
2010 152 61 40.1
Combined 3126 1467 46.9
Years for which no isolates were provided are not listed; % values are not displayed where the numbers of isolates of S. aureus were <10.
lates a Includes Nicaragua (Nicaragua is not listed separately as only 4 iso
in 2004 to 20.7% in 2008 but then decreased to 8.2% in 2010
(Table 2).
MSSA susceptibility to minocycline was high across Latin
America (99.2%), the lowest rate being reported in Brazil
(95.6%). MRSA susceptibility to minocycline was only slightly
lower (97.0%) than the MSSA susceptibility rate. Minocycline
non-susceptible MRSA were reported among all Latin Amer-
ican countries with the exceptions of Chile, El Salvador,
Honduras, Panama, and Puerto Rico. The lowest levels of
minocycline-susceptible MRSA were reported in Brazil (88.2%)
and Colombia (92.7%) (Table 2).
Discussion
After a period of increase in the 1990s and 2000s, the preva-
lence of MRSA has declined in some regions in recent years.10
Picao et al.11 reported on the prevalence of MRSA in Latin
America between 1997 and 2006 as part of the SENTRY study.
They found that more  than one-third of S. aureus isolates
(37.3%) were methicillin-resistant, increasing signiﬁcantly in
prevalence from 33.8% in 1997 to 40.2% in 2006 (p = 0.007). Data
from the current study suggest that this increase in MRSA
levels in Latin America has halted: MRSA numbers remained
relatively stable between 2004 (44.6%) and 2010 (40.1%).
Rossi et al.7 previously reported on rates of antimicrobial
resistance in Latin America among S. aureus (as well as other
important pathogens) between 2004 and 2007 as part of T.E.S.T.
There has been little change in MRSA prevalence since this
previous study: Rossi et al. reported 48.3% MRSA in Latin Amer-
ica between 2004 and 2007, compared with 46.9% reported
in the current study between 2004 and 2010. Two notewor-
thy changes were observed between Rossi et al.’s data and
the current study: in Colombia, MRSA decreased from 53.8%
to 37.1%, while MRSA increased in Venezuela from 19.0% to
49.2%. These changes could be due in part to relatively smallof S. aureus (2 of which were MRSA) were collected, all in 2006).
sample sizes collected in these countries during the early
years of the T.E.S.T. study. Another important factor could be
contributions from different centers over the course of the
study period: 66 centers contributed data to the current study
compared to 33 centers for the 2008 report by Rossi.
In a recent study on Latin American MRSA, Reyes et al.12
reported on the prevalence of MRSA in four countries,
including Colombia and Venezuela, between 2006 and 2008.
Compared with the current study, the authors reported higher
rates of MRSA in Colombia (45% compared with 37.1% reported
here) but lower rates in Venezuela (26% compared with 49.2%).
These differences are most likely due to real differences in
local prevalence of MRSA: Sader et al.13 showed that there is
considerable variation in MRSA rates among hospitals in the
same country as well as among countries in Latin America.
These discrepancies could also be due in part to the collection
of relatively low numbers of isolates in these two countries:
only 69 and 318 MRSA isolates were identiﬁed from Venezuela
and Colombia, respectively, by Reyes et al.12 while only 92 and
165 isolates (respectively) were collected in T.E.S.T. between
2004 and 2010.
The good activity of tigecycline, linezolid, and vancomycin
against MRSA reported here is supported by other research in
Latin America. Gales et al.13 reported 100% susceptibility to
tigecycline, vancomycin, and linezolid among 217 oxacillin-
resistant S. aureus isolates collected across Latin America as
part of the SENTRY study during 2000–2002. In a subsequent
SENTRY report, Sader et al. (2009)14 showed that >99.9% of S.
aureus isolates collected in Latin America between January
2003 and December 2008 were susceptible to linezolid and
vancomycin. Fernández Canigia et al.15 reported 100% tige-
cycline susceptibility among 878 clinical isolates of S. aureus
from Argentina between November 2005 and October 2006
regardless of methicillin resistance. Casellas et al.16 reported
an MIC90 of 0.25 mg/L for tigecycline against 223 isolates of
S. aureus collected in nine centers across Argentina, while
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Table 2 – In vitro activity of tigecycline and comparatorsa (% susceptibility) against isolates of methicillin-susceptible Staphylococcus aureus (MSSA) and
methicillin-resistant S. aureus (MRSA) across Latin Americab between 2004 and 2010.
Argentina Brazil Chile Colombia Guatemala Mexico Panama Venezuela Latin America
MSSA MRSA MSSA MRSA MSSA MRSA MSSA MRSA MSSA MRSA MSSA MRSA MSSA MRSA MSSA MRSA MSSA MRSA
Levoﬂoxacin
2004 100 3.6 – – –  – – – – – – – – – – – 100 3.4
2005 95.3 15.3 100 10  100 0.0 – – – – – 0.0 – – – – 97.0 10.7
2006 93.3 26.9 100 6.7 93.3 8.0 93.8 7.5 100 4.3 93.7 5.5 85.7 54.5 94.1 – 94.3 13.9
2007 96.0 36.5 93.3 10 93.3 0.0 92.9 – – 0 95.3 7.4 100 – 97.2 36.4 96.0 19.1
2008 88.6 40.7 92.3 2.9 95.8 0.0 98.0 34.4 – 0 93.9 8.4 87.5 20.0 92.9 40.0 93.6 20.7
2009 94.4 34.4 95.5 2.8 93.8 3.1 100 31.1 100 0 87.3 6.4 88.2 – 100 40.0 94.3 15.8
2010 82.4 – – – – – 100 10.0 – – 78.3 4.5 – – – – 91.2 8.2
2004–2010 93.5 29.7 95.6 5.5 95.7 2.0 98.2 25.5 100 0.8 91.8 6.4 90.8 35.5 96.8 38.0 94.6 16.2
Minocycline
2004 100 96.4 – – – – – – – – – – – – – – 100 96.6
2005 100 100 94.7 96.7 100 100 – – – – – 100 – – – – 99.3 99.2
2006 100 100 90.0 80.0 100 100 100 100 100 100 100 100 100 100 100 – 99.6 98.4
2007 100 97.3 100 100 100 100 100 – – 100 98.8 100 100 – 100 100 99.6 99.1
2008 100 98.8 96.2 71.4 100 100 99 85.2 – 95.5 99.4 94.4 100 100 100 100 99.3 92.4
2009 100 96.9 95.5 97.2 100 100 98.7 93.3 100 98.1 99.2 100 94.1 – 96.2 98.3 98.6 98.1
2010 100 – – – – – 95.9 100 – – 100 97.7 – – – – 97.8 98.4
2004–2010 100 98.3  95.6 88.2 100 100 98.6 92.7 100 98.3 99.4 98.0 98.5 100 98.9 98.9 99.2 97.0
a All isolates of S. aureus were susceptible to linezolid and vancomycin, so data for these antimicrobials are not listed here. Only 3 (0.1%) tigecycline non-susceptible isolates were collected (1 in
Honduras and 2 in El Salvador, all in 2009), so tigecycline data are not listed here.
b Data were only contributed in a single year for El Salvador (2009: S. aureus, n = 34; MRSA, n = 19), Jamaica (2006: S. aureus, n = 25; MRSA, n = 4), Nicaragua (2006: S. aureus, n = 4; MRSA, n = 2) and Puerto
Rico (2006: S. aureus, n = 23; MRSA, n = 17) so are not listed here.
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Silva-Sanchez et al.17 recounted an MIC90 of 0.125 mg/L for
tigecycline against 482 MRSA isolates from Mexico. In a global
review of Gram-positive pathogens (including Latin America)
as part of the ZAAPS program, Jones et al.18 did not report
any linezolid resistance among 3240 S. aureus isolates in 2008.
Minocycline also performed well against MRSA in the current
study, a result supported by Reyes et al.12 who reported low-
level minocycline resistance (1%; 8/651) among MRSA isolates
collected in Colombia, Ecuador, Peru, and Venezuela between
2006 and 2008.
Vancomycin is widely used in Latin America for the
treatment of MRSA infections.19 While no VRSA isolates (or
vancomycin-intermediate MRSA [VISA] isolates) were identi-
ﬁed in the current study, both MRSA and MSSA isolates with
vancomycin MIC90s of 2 mg/L (the upper limit of vancomycin
susceptibility) were observed. Isolates of MRSA with reduced
susceptibility to vancomycin have been identiﬁed previously
across Latin America.20–24 A decrease in the activity of van-
comycin in clinical settings is seen by some as a cause for
concern Stefani and Goglio,2 and alternative approaches to
MRSA treatment must be made available if VISA or VRSA fre-
quency increases in the region.
One potential source for error in any surveillance study is
inconsistent methodologies being used in different centers.
All MICs in T.E.S.T. were determined locally using CLSI-deﬁned
broth microdilution methodology (Sensititre® plates [TREK
Diagnostic Systems, West Sussex, England] or MicroScan®
panels [Siemens, Sacramento, CA, USA]).8 Antimicrobial sus-
ceptibility was determined using CLSI interpretive criteria.9 In
order to ensure consistent results between centers and reduce
the potential for experimental error, standardized procedures
were utilized at all participating centers. These include the
use of the same materials (MIC panels, microdilution broth,
inoculators) as well as procedures (quality control [QC] proce-
dures, QC ranges) as the central lab, as detailed by CLSI.8,9 QC
strain S. aureus ATCC 29213 was cultured on each day of MIC
testing to ensure that collected MIC  values fell into acceptable
QC ranges.
Surveillance studies are often inﬂuenced by study biases
Bax et al.25 Although 66 centers across Latin America par-
ticipated in this study, only one center contributed isolates
in all six years of the study. These inconsistencies in center
participation will most likely have inﬂuenced the longitudinal
susceptibilities reported here.
Conclusions
Surveillance studies such at T.E.S.T. are essential tools in our
efforts to monitor the spread of problematic pathogens such
as MRSA, both regionally and globally. Surveillance provides
information critical to healthcare professionals for making
informed decisions regarding appropriate antimicrobial ther-
apy to prevent and treat infection, described succinctly by
Johnson10 as ‘information for action’. Results from the Tigecy-
cline Evaluation and Surveillance Trial, which has been active
since 2004, indicate that linezolid, vancomycin and tigecycline
are all highly active against methicillin-resistant S. aureus iso-
lates from the Latin America region.
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